How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski cover art

How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski

How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski

Listen for free

View show details

About this listen

Send us a text

In this episode of the WTR Small-Cap | Biotech Spotlight Crossover, Water Tower Research’s Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company’s pioneering work in neuroplastogen drug development and delivery technologies.

Dr. Chris Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape.

Tune in to learn more about Psilera’s vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.

What listeners say about How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.